XRCC2 Inhibitors

The chemical class of XRCC2 inhibitors encompasses a range of compounds that indirectly modulate the function of XRCC2, primarily through their influence on DNA repair pathways and related cellular processes. These compounds do not directly target XRCC2 but impact the cellular environment and pathways in which XRCC2 operates, particularly homologous recombination repair of DNA double-strand breaks. PARP inhibitors like Olaparib, Rucaparib, Niraparib, Veliparib, and Talazoparib are key components of this class. By inhibiting PARP, an enzyme crucial for single-strand break repair, these compounds enhance the dependency of cells on homologous recombination for DNA repair, thereby potentially influencing the role of XRCC2 in this pathway. For example, Olaparib and Rucaparib could indirectly affect XRCC2's function by shifting the cellular repair mechanisms towards pathways where XRCC2 is essential.

Additionally, compounds such as Mitomycin C, Cisplatin, Camptothecin, Etoposide, Bleomycin, Doxorubicin, and Hydroxyurea, which interact with DNA and affect various aspects of DNA metabolism and repair, are included in this class. These compounds induce DNA damage in forms like crosslinks, adducts, or strand breaks, potentially impacting the DNA repair processes where XRCC2 is involved. For instance, Mitomycin C and Cisplatin, known for inducing DNA crosslinks, could increase the reliance on homologous recombination repair pathways, thereby affecting XRCC2's activity. Similarly, topoisomerase inhibitors like Camptothecin and Etoposide, and agents that cause DNA strand breaks like Bleomycin and Doxorubicin, might influence the functional dynamics of XRCC2 in the DNA repair process.